Skip to content

Nabriva Therapeutics plc

Delisted

CIK 1641640fmd_1A16DDH3GWEAVZF7XEHNY7S1T0Manufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Jan 01, 2014 to Jun 30, 2023, 35 periods

Latest annual · FY2022

Millions
Total revenues
37
Gross profit
8
Operating income
(55)
Net income
(57)
Free cash flow
(37)

Latest quarter · Q2 FY2023

Millions
Total revenues
2
Gross profit
(7)
Operating income
(12)
Net income
(12)
Free cash flow
1
Open Financials

Key stats

Open Analysis

Compound annual growth

Revenue, 3 yearsFY2019 to FY2022
+57.3%
Revenue, 5 yearsFY2017 to FY2022
+47.3%
Net income, 5 yearsFY2017 to FY2022
n/m

Nabriva Therapeutics plc financials: quick answers

Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.

MetricFY2022FY2021ChangeSource
Revenue$36.9 million$28.9 million+27.8%10-K 2023-04-17 · proof
Gross profit$8.4 million$15.7 million-46.9%10-K 2023-04-17 · proof
Operating income-$55.5 million-$48.5 million10-K 2023-04-17 · proof
Net income-$57.2 million-$49.5 million10-K 2023-04-17 · proof
Cash from operating activities-$36.7 million-$59.6 million10-K 2023-04-17 · proof
Free cash flow-$36.9 million-$59.6 million10-K 2023-04-17 · proof
Total assets$31.8 million$80.9 million-60.7%10-K 2023-04-17 · proof
Total liabilities$28.5 million$27.6 million+3.3%10-K 2023-04-17 · proof
Cash and cash equivalents$12.4 million$47.7 million-74%10-K 2023-04-17 · proof
Total debt$5.2 million$8 million-35%10-K 2023-04-17 · proof
What was Nabriva Therapeutics plc's revenue in fiscal 2022?
Nabriva Therapeutics plc reported revenue of $36.9 million for fiscal 2022 (the year ended Dec 31, 2022), against $28.9 million the year before (+27.8%). Source: the 10-K filed with the SEC on Apr 17, 2023. SEC
What was Nabriva Therapeutics plc's gross profit in fiscal 2022?
Nabriva Therapeutics plc reported gross profit of $8.4 million for fiscal 2022 (the year ended Dec 31, 2022), against $15.7 million the year before (-46.9%). Source: the 10-K filed with the SEC on Apr 17, 2023. SEC
What was Nabriva Therapeutics plc's operating income in fiscal 2022?
Nabriva Therapeutics plc reported operating income of -$55.5 million for fiscal 2022 (the year ended Dec 31, 2022), against -$48.5 million the year before. Source: the 10-K filed with the SEC on Apr 17, 2023. SEC
What was Nabriva Therapeutics plc's net income in fiscal 2022?
Nabriva Therapeutics plc reported net income of -$57.2 million for fiscal 2022 (the year ended Dec 31, 2022), against -$49.5 million the year before. Source: the 10-K filed with the SEC on Apr 17, 2023. SEC
What was Nabriva Therapeutics plc's cash from operating activities in fiscal 2022?
Nabriva Therapeutics plc reported cash from operating activities of -$36.7 million for fiscal 2022 (the year ended Dec 31, 2022), against -$59.6 million the year before. Source: the 10-K filed with the SEC on Apr 17, 2023. SEC
What was Nabriva Therapeutics plc's free cash flow in fiscal 2022?
Nabriva Therapeutics plc reported free cash flow of -$36.9 million for fiscal 2022 (the year ended Dec 31, 2022), against -$59.6 million the year before. Source: the 10-K filed with the SEC on Apr 17, 2023. SEC
What are Nabriva Therapeutics plc's total assets?
As of Dec 31, 2022, Nabriva Therapeutics plc reported total assets of $31.8 million, against $80.9 million a year earlier (-60.7%). Source: the 10-K filed with the SEC on Apr 17, 2023. SEC
What are Nabriva Therapeutics plc's total liabilities?
As of Dec 31, 2022, Nabriva Therapeutics plc reported total liabilities of $28.5 million, against $27.6 million a year earlier (+3.3%). Source: the 10-K filed with the SEC on Apr 17, 2023. SEC
What are Nabriva Therapeutics plc's cash and cash equivalents?
As of Dec 31, 2022, Nabriva Therapeutics plc reported cash and cash equivalents of $12.4 million, against $47.7 million a year earlier (-74%). Source: the 10-K filed with the SEC on Apr 17, 2023. SEC
What is Nabriva Therapeutics plc's total debt?
As of Dec 31, 2022, Nabriva Therapeutics plc reported total debt of $5.2 million, against $8 million a year earlier (-35%). Source: the 10-K filed with the SEC on Apr 17, 2023. SEC

Read from the FinancialMD API on Nov 14, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.

The same numbers for an agent, with proof on every value:

curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1641640&period_type=annual&limit=5"

Information only, not investment advice.